Stimulator of Interferon Genes in a Fine-Tuner, but not a Prime Mover, of Kidney Inflammation.
Syeda MZ, Yeung ESH, Hong LYQ, Advani SL, Liu Y, Geldenhuys L, Siddiqi FS, Yerra VG, Batchu SN, Advani A. American Journal of Pathology, 2026;196:515-531.
Biphasic actions of the adenosine A2a receptor antagonist istradefylline in mice with obstructive uropathy.
Yeung ESH, Tran DT, Batchu SN, Advani SL, Liu Y, Kaur H, Yuen DA, Aslam R, Luk CT, Advani A. Scientific Reports, 2025;15:41110.
European Association for the Study of Diabetes (EASD) Standard Operating Procedure for the development of guidelines
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes.
Tran DT, Yeung ESH, Hong LYQ, Kaur H, Advani SL, Liu Y, Syeda MZ, Batchu SN, Advani A. Diabetology and Metabolic Syndrome 2024;16:283.
Patient, family and caregiver engagement in diabetes care: a scoping review protocol.
Chamoun D, Ramasamy M, Ziegler C, Yu CH, Wijeyesekera P, Advani A, Pritlove C. BMJ Open 2024;14:e086772.
Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with Type 1 diabetes.
Kugathasan L, Sridhar VS, Lytvyn Y, Lovblom LE, Berkins PA, Advani A, Cherney DZI. Diabetes Research and Clinical Practice 2024;213:111764.
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold SA, Haase C, Xu Y, Forbes JM, Crawford S, Ramm G, Harcourt BE, Jandeleit-Dahm K, Advani A, Murphy AJ, Timmermann DB, Karihaloo A, Knudsen LB, El-Osta A, Drucker DJ, Cooper ME, Coughlan MT.. Kidney International. 2024;105:132-149.
Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes.
Interferons and interferon-related pathways in heart disease.
Tran DT, Batchu SN, Advani A. Frontiers in Cardiovascular Medicine. 2024;11:1354343.
Preventing occludin tight-junction disruption via inhibition of microRNA-193b-5p attenuates viral load and influenza-induced lung injury.
Vaswani CM, Varkouhi AK, Gupta S, Ektesabi AM, Tsoporis JN, Yousef S, Plant PJ, da Silva AL, Cen Y, Tseng YC, Batah SS, Fabro AT, Advani SL, Advani A, Leong-Poi H, Marshall JC, Garcia CC, Rocco PRM, Albaiceta GM, Sebastian-Bolz S, Watts TH, Moraes TJ, Capelozzi VL, Dos Santos CC. Molecular Therapy. 2023;31:2681-2701.
Altered expression, but small contribution, of the histone demethylase KDM6A in obstructive uropathy in mice.
Hong LYQ, Yeung ESH, Tran DT, Yerra VG, Kaur H, Kabir MDG, Advani SL, Liu Y, Batchu SN, Advani A. Disease Models & Mechanisms. 2023;16:dmm049991.
Pressure overload induces ISG15 to facilitate adverse
ventricular remodeling and promote heart failure
Yerra VG, Batchu SN, Kaur H, Kabir MDG, Liu Y, Advani
SL, Tran DT, Sadeghian S, Sedrak P, Billia F, Kuzmanov
U, Gramolini AO, Qasrawi DO, Petrotchenko EV, Borchers
CH, Connelly KA, Advani A. The Journal of Clinical Investigation. 2023;133:e161453.
Single cell G-protein coupled receptor profiling of
Transcription factor 21 expressing activated kidney
fibroblasts
Kaur H, Yerra VG, Batchu SN, Tran DT, Kabir MDG, Liu Y,
Advani SL, Sedrak P, Geldenhuys L, Tennankore KK, Poyah
P, Siddiqi FS, Advani A. British Journal of Pharmacology. 2023;133:Epub ahead of print April 28.
The anti-hypertensive effects of sodium-glucose
cotransporter-2 inhibitors.
Kugathasan L, Dubrofsky L, Advani A, Cherney DZI. Expert Reviews in Cardiovascular Therapy. 2023;21:15-34.
Sustained improvement in glycemic control in emerging
adults with Type 1 diabetes 2 years after the start of
the COVID-19 pandemic.
Swaich H, Advani A. Diabetes Therapy. 2023;14:153-165.
The SGLT2i dapagliflozin reduces RV mass independent of
changes in RV pressure induced by pulmonary artery
banding.
Connelly KA, Wu E, Visram A, Friedberg MK, Batchu SN,
Yerra VG, Thai K, Nghiem L, Zhang Y, Kabir G, Desjardins
JF, Advani A, Gilbert RE. Cardiovascular Drugs and Therapy. 2022;
Epub ahead of print Sep 29.
DJ-1 binds to rubicon to impair LC-3 associated
phagocytosis.
Gupta S, Amatullah H, Tsoporis JN, Wei K, Monteiro APT,
Ektesabi AM, Varkouhi AK, Vaswani CM, Formosa A, Fabro
AT, Batchu SN, Fjell C, Russell JA, Walley KR, Advani A,
Parker TG, Marshall JC, Rocco PRM, Fairn GD, Mak TW, Dos
Santos CC. Cell Death and Differentiation. 2022;29:2024-2033.
Role of CCR2-positive cardiac macrophages in
pathological ventricular remodeling.
Yerra VG, Advani A. Biomedicines. 2022;10:661.
Perceptions and correlates of distress due to the
COVID-19 pandemic and stress management strategies among
people with diabetes: a mixed methods study.
Im J, Escudero C, Zhang K, Choi D, Sivakumar A, Booth
GL, Sale J, Pritlove C, Advani A, Yu CH. Canadian Journal of Diabetes. 2022;46:253-261.
Empagliflozin disrupts a Tnfrsf12a-mediated feed forward
loop trial that promotes left ventricular hypertrophy.
Yerra VG, Batchu SN, Kabir G, Advani SL, Liu Y, Siddiqi
FS, Connelly KA, Advani A. Cardiovascular Drugs and Therapy. 2022;36:619-632
Lung and kidney ACE2 and TMPRSS2 in renin angiotensin
system blocker treated comorbid diabetic mice mimicking
host factors that have been linked to severe COVID-19.
Batchu SN, Kaur H, Yerra VG, Advani SL, Kabir MG, Liu Y,
Klein T, Advani A. Diabetes. 2021;70:759-771.
